Adam Dubow Sells 4,646 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) General Counsel Adam Dubow sold 4,646 shares of Day One Biopharmaceuticals stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $55,566.16. Following the completion of the sale, the general counsel now owns 39,602 shares in the company, valued at $473,639.92. This represents a 10.50 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Day One Biopharmaceuticals Stock Up 1.6 %

Shares of DAWN opened at $12.43 on Friday. Day One Biopharmaceuticals, Inc. has a fifty-two week low of $11.13 and a fifty-two week high of $18.07. The company has a market cap of $1.25 billion, a P/E ratio of -12.07 and a beta of -1.46. The firm’s 50 day moving average price is $12.37 and its 200 day moving average price is $13.47.

Institutional Trading of Day One Biopharmaceuticals

Large investors have recently modified their holdings of the stock. GF Fund Management CO. LTD. purchased a new position in Day One Biopharmaceuticals in the fourth quarter valued at $27,000. R Squared Ltd purchased a new stake in Day One Biopharmaceuticals during the 4th quarter worth about $31,000. Mirae Asset Global Investments Co. Ltd. raised its position in Day One Biopharmaceuticals by 38.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock valued at $51,000 after purchasing an additional 1,002 shares in the last quarter. Quest Partners LLC boosted its stake in shares of Day One Biopharmaceuticals by 9,238.6% in the 3rd quarter. Quest Partners LLC now owns 7,751 shares of the company’s stock valued at $108,000 after buying an additional 7,668 shares during the period. Finally, Tower Research Capital LLC TRC grew its position in shares of Day One Biopharmaceuticals by 911.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 10,657 shares of the company’s stock worth $135,000 after buying an additional 9,603 shares in the last quarter. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. TD Cowen raised Day One Biopharmaceuticals to a “strong-buy” rating in a research report on Monday, November 4th. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st. The Goldman Sachs Group decreased their price objective on shares of Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating on the stock in a report on Monday, February 10th. Needham & Company LLC reiterated a “buy” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a report on Monday, January 13th. Finally, Bank of America decreased their price target on Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $35.71.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.